NCT04499339View on ClinicalTrials.gov

A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

SLAMF7 CAR-T

Single infusion of autologous SLAMF7 CAR-T cells

Trial Locations (3)

31008

Clinical Trials Unit, Clinica Universidad de Navarra, Pamplona

59037

Centre Hospitalier Universitaire de Lille, Lille

97080

Early Clinical Trial Unit University Hospital Wuerzburg, Würzburg

All Listed Sponsors
collaborator

European Union

OTHER

lead

Wuerzburg University Hospital

OTHER